Max
08-19-2002, 09:50 AM
Adenosine Therapeutics Announces Appointment of Dr. Michael Williams To the Board of Directors
8/19/2002 8:01:00 AM
CHARLOTTESVILLE, Va., Aug 19, 2002 /PRNewswire via COMTEX/ -- Adenosine Therapeutics, LLC announced today the appointment of Michael Williams, Ph.D., D.Sc., to its Board of Directors. Dr. Williams is an expert on purine-based pharmaceuticals with extensive experience in the pharmaceutical industry.
CBS MARKETWATCH TOP NEWS
Retail, tech rally fires up U.S. stocks
Lowe's earnings ahead of estimtes
AstraZeneca hit by anti-cancer drug disappointment
OSI leads biotech retreat
Sign up for FREE e-newsletters
TRACK THESE TOPICS
My Portfolio Alerts
Company: Abbott Laboratories Add
Create
Create A Portfolio | Create An Alert
Dr. Williams earned his Ph.D. in Neurochemistry from the Institute of Psychiatry, University of London in 1974 and a D.Sc. degree from the same University in 1987. He has been actively involved in adenosine-based research for over 30 years. He worked in the ethical pharmaceutical industry in the United States for 26 years before retiring from the Pharmaceutical Products Division of Abbott Laboratories in December, 2000, where he was Divisional Vice President, Neurological and Urological Diseases Research. Since then, he has worked as both an industry consultant, most notably with Genset, SA in Paris in the field of psychiatric genomics and, until August, 2002, as General Manager and Vice President, Drug Discovery for Molecumetics, a chemistry-based biotech company located in Bellevue, Washington.
Prior to his tenure at Abbott Laboratories, Dr. Williams worked at Merck Research Laboratories (1976-1983), Nova Pharmaceutical (1983-1984), and CIBA- Geigy Pharmaceuticals (1984-1989). At CIBA-Geigy, he was part of the research team involved in the discovery of CGS 21680, the first selective agonist for the adenosine A2A receptor. He is on the Scientific Advisory Boards of Elan Pharmaceuticals, Sigma-Aldrich, and Targacept Inc., and is Chairman of the Board of Antalium, a biotech joint venture between McGill University and NeuroSearch which focuses on drug discovery in the area of pain. He is also Adjunct Professor in the Department of Molecular Pharmacology and Biological Chemistry at Northwestern University School of Medicine in Chicago, Editor-in- Chief of Current Opinions in Investigational Drugs and Drug Development Research, and an Associate Editor for the Journal of Pharmacology and Experimental Therapeutics.
"We are honored to have Dr. Williams as a member of our Board of Directors," said Robert S. Capon, CEO and co-founder of Adenosine Therapeutics, LLC. "His 30 years of experience in adenosine research in the pharmaceutical industry complements and enhances the Board's wide-range of scientific and business expertise."
Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine receptor subtypes. Candidates for drug development are identified and screened using the Company's state of the art platform technology. The Company was founded with the goal of bringing new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include sepsis, anthrax therapy, heart attack, ischemia-reperfusion injury, vascular injury, stroke, spinal cord injury, organ transplantation, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, and evoking new blood vessel formation in circulatory insufficiency.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X07379170
SOURCE Adenosine Therapeutics, LLC
CONTACT: Robert Capon, CEO, of Adenosine Therapeutics, LLC, +1-434-971-6800URL: http://www.adenosinetherapeutics.comhttp://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
==============================
"With every scientific advance, we grow closer to unlocking the mysteries of life and creation. But what have we gained if in the process, we lose our humanity. The most powerful thing we pass along to our children may not reside in the genes, but in the soul."
The Outer Limits(Criminal Nature)
8/19/2002 8:01:00 AM
CHARLOTTESVILLE, Va., Aug 19, 2002 /PRNewswire via COMTEX/ -- Adenosine Therapeutics, LLC announced today the appointment of Michael Williams, Ph.D., D.Sc., to its Board of Directors. Dr. Williams is an expert on purine-based pharmaceuticals with extensive experience in the pharmaceutical industry.
CBS MARKETWATCH TOP NEWS
Retail, tech rally fires up U.S. stocks
Lowe's earnings ahead of estimtes
AstraZeneca hit by anti-cancer drug disappointment
OSI leads biotech retreat
Sign up for FREE e-newsletters
TRACK THESE TOPICS
My Portfolio Alerts
Company: Abbott Laboratories Add
Create
Create A Portfolio | Create An Alert
Dr. Williams earned his Ph.D. in Neurochemistry from the Institute of Psychiatry, University of London in 1974 and a D.Sc. degree from the same University in 1987. He has been actively involved in adenosine-based research for over 30 years. He worked in the ethical pharmaceutical industry in the United States for 26 years before retiring from the Pharmaceutical Products Division of Abbott Laboratories in December, 2000, where he was Divisional Vice President, Neurological and Urological Diseases Research. Since then, he has worked as both an industry consultant, most notably with Genset, SA in Paris in the field of psychiatric genomics and, until August, 2002, as General Manager and Vice President, Drug Discovery for Molecumetics, a chemistry-based biotech company located in Bellevue, Washington.
Prior to his tenure at Abbott Laboratories, Dr. Williams worked at Merck Research Laboratories (1976-1983), Nova Pharmaceutical (1983-1984), and CIBA- Geigy Pharmaceuticals (1984-1989). At CIBA-Geigy, he was part of the research team involved in the discovery of CGS 21680, the first selective agonist for the adenosine A2A receptor. He is on the Scientific Advisory Boards of Elan Pharmaceuticals, Sigma-Aldrich, and Targacept Inc., and is Chairman of the Board of Antalium, a biotech joint venture between McGill University and NeuroSearch which focuses on drug discovery in the area of pain. He is also Adjunct Professor in the Department of Molecular Pharmacology and Biological Chemistry at Northwestern University School of Medicine in Chicago, Editor-in- Chief of Current Opinions in Investigational Drugs and Drug Development Research, and an Associate Editor for the Journal of Pharmacology and Experimental Therapeutics.
"We are honored to have Dr. Williams as a member of our Board of Directors," said Robert S. Capon, CEO and co-founder of Adenosine Therapeutics, LLC. "His 30 years of experience in adenosine research in the pharmaceutical industry complements and enhances the Board's wide-range of scientific and business expertise."
Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine receptor subtypes. Candidates for drug development are identified and screened using the Company's state of the art platform technology. The Company was founded with the goal of bringing new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include sepsis, anthrax therapy, heart attack, ischemia-reperfusion injury, vascular injury, stroke, spinal cord injury, organ transplantation, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, and evoking new blood vessel formation in circulatory insufficiency.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X07379170
SOURCE Adenosine Therapeutics, LLC
CONTACT: Robert Capon, CEO, of Adenosine Therapeutics, LLC, +1-434-971-6800URL: http://www.adenosinetherapeutics.comhttp://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
==============================
"With every scientific advance, we grow closer to unlocking the mysteries of life and creation. But what have we gained if in the process, we lose our humanity. The most powerful thing we pass along to our children may not reside in the genes, but in the soul."
The Outer Limits(Criminal Nature)